Praxis Precision Medicines reported that ulixacaltamide met primary endpoints in two pivotal Phase 3 trials for essential tremor, delivering both symptomatic improvement and maintenance of effect in a randomized‑withdrawal design. The company says the data support an NDA submission planned for early 2026 and that the program enrolled large numbers reflecting substantial unmet need. Investors reacted strongly to the dual readouts, sending shares sharply higher. The readouts close a chapter of uncertainty after an earlier interim analysis raised concerns; company statements say the full datasets clarify efficacy and tolerability across endpoints relevant to regulators and prescribers.